Consensus Legend Biotech Corporation

Equities

LEGN

US52490G1022

Market Closed - Nasdaq 21:00:00 18/07/2024 BST 5-day change 1st Jan Change
58.24 USD +5.89% Intraday chart for Legend Biotech Corporation +20.08% -3.21%

Evolution of the average Target Price on Legend Biotech Corporation

Price target over the last 5 years

History of analyst recommendation changes

9e8cdc.JS2fkzeAJBUOOiJtwBzT-G-kYKfJ8jifAuPie12Ybh0.RE75wATTcXFXdntbk3-UlyLTU-uet13Fe6SNPTDJJkJEe8zJbbdlOE1Wew~871ce5dd0deccde15df6903316ed1e68
TD Cowen Adjusts Legend Biotech Price Target to $67 From $71, Maintains Buy Rating MT
Truist Securities Initiates Legend Biotech With Buy Rating, $88 Price Target MT
HC Wainwright Adjusts Legend Biotech Price Target to $73 From $86, Maintains Buy Rating MT
Deutsche Bank Starts Legend Biotech With Buy Rating MT
HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating MT
RBC Adjusts Price Target on Legend Biotech to $86 From $85 on Model Updates, Maintains Outperform Rating MT
Scotiabank Upgrades Legend Biotech to Sector Outperform From Sector Perform, Price Target is $65 MT
Cantor Fitzgerald Initiates Legend Biotech With Overweight Rating MT
UBS Adjusts Legend Biotech Price Target to $81 From $76, Maintains Buy Rating MT
Raymond James Starts Legend Biotech With Outperform Rating, $86 Price Target MT
RBC Trims Price Target on Legend Biotech to $85 From $86, Keeps Outperform Rating MT
Scotiabank Initiates Legend Biotech With Sector Perform Rating, $65 Price Target MT
HC Wainwright Raises Price Target on Legend Biotech to $87 From $86, Keeps Buy Rating MT
HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $85, Keeps Buy Rating MT
Barclays Adjusts Price Target on Legend Biotech to $93 From $92, Maintains Overweight Rating MT
Barclays Adjusts Price Target on Legend Biotech to $92 From $90, Maintains Overweight Rating MT
HC Wainwright Adjusts Price Target on Legend Biotech to $85 From $82, Maintains Buy Rating MT
Morgan Stanley Raises Price Target on Legend Biotech to $85 From $65, Maintains Overweight Rating MT
BTIG Raises Price Target on Legend Biotech to $90 From $85, Maintains Buy Rating MT
HC Wainwright Adjusts Legend Biotech Price Target to $82 From $77, Maintains Buy Rating MT
William Blair Initiates Legend Biotech at Market Perform MT
Daiwa Securities Initiates Legend Biotech at Buy Rating MT
Barclays Adjusts Price Target on Legend Biotech to $90 From $65, Keeps Overweight Rating MT
RBC Boosts Price Target on Legend Biotech to $83 From $74, Cites Greater Confidence in Manufacturing Progress, Keeps Outperform Rating MT
BMO Capital Adjusts Price Target on Legend Biotech to $90 From $79, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
55 USD
Average target price
82.63 USD
Spread / Average Target
+50.24%
High Price Target
95 USD
Spread / Highest target
+72.73%
Low Price Target
60 USD
Spread / Lowest Target
+9.09%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Legend Biotech Corporation

Truist Securities
HC Wainwright
Deutsche Bank Securities
RBC Capital Markets
Scotiabank
Cantor Fitzgerald
UBS
Raymond James
Barclays
Morgan Stanley
BTIG
William Blair & Co.
Daiwa Securities
BMO Capital
JPMorgan Chase
Piper Sandler
Cowen
Guggenheim
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
  1. Stock Market
  2. Equities
  3. LEGN Stock
  4. Consensus Legend Biotech Corporation